Product Center
Yisuda®Suraxavir Marboxil Tablets
Yisuda®Suraxavir Marboxil Tablets are a novel antiviral medication for the treatment of uncomplicated influenza A and B in previously healthy adolescents aged 12 and above, and adults.
Aurantii® Fructus Immaturus Total Flavonoids Tablet
Aurantii® Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency).
Xiyanping Injection
Xiyanping Injection is a traditional Chinese medicine injection made from total sulfated andrographolide, a key component of Andrographis paniculata. It is part of the National “12th Five-Year Plan” Major Innovative Drug Discovery Project.
Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Bangkaxin®Esomeprazole Magnesium Enteric-coated Tablets
Bangkaxin® Esomeprazole Magnesium Enteric-coated Tablets are a new generation of proton pump inhibitors (PPIs), approved as a Class 4 chemical drug. It is the only esomeprazole magnesium enteric-coated tablet in China that is bioequivalent to the original brand. It is clinically used for the prevention and treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, stress ulcers, Helicobacter pylori eradication, and drug-induced gastric mucosal injury. It is widely used in clinical practice and is a first-line choice for acid suppression therapy and ulcer prevention and treatment.
Zebeining® Palbociclib Capsuless
Zebeining® Palbociclib Capsuless are an oral CDK4/6 inhibitor that selectively targets and inhibits the activity of the CDK4/6-Cyclin D1 complex. This prevents tumor cells from passing through the G1 to S phase checkpoint, blocking the cell cycle and inhibiting tumor cell proliferation.It is primarily used for the treatment of hormone receptor-positive (HR+), HER2-negative locally advanced or metastatic breast cancer, in combination with aromatase inhibitors as initial endocrine therapy for postmenopausal women.
Weibiai® Roxadustat Capsules
Roxadustat is the world’s first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and is indicated for the treatment of anemia caused by chronic kidney disease (CKD), including both dialysis and non-dialysis patients.
Shuxinqing®Beraprost Sodium Tablets
Beraprost sodium works by activating prostacyclin receptors on platelets and vascular smooth muscle cells, which in turn stimulates adenylate cyclase, raises intracellular cAMP levels, inhibits calcium influx, and reduces thromboxane A2 production.
Zebixin® Mirabegron Sustained-release Tablets
Mirabegron is the world's first β3-adrenoceptor agonist approved for treating overactive bladder (OAB) in adults.
Ningqingtuo® Nifedipine Extended-Release Tablets
Ningqingtuo® Nifedipine Extended-Release Tablets are dihydropyridine calcium channel blockers, indicated for the treatment of hypertension, coronary artery disease, and stable chronic angina (exertional angina).
Ningqingtan® Acetylcysteine Effervescent Tablets
Ningqingtan® Acetylcysteine Effervescent Tablets are indicated for the treatment of chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB), emphysema (PE), and other chronic respiratory diseases characterized by excessive and thick mucus secretion.
Zesuoxin® Tamsulosin Hydrochloride Sustained Release Capsules
Benign Prostatic Hyperplasia (BPH) is the most common cause of urinary disorders in middle-aged and elderly men. Tamsulosin hydrochloride is a highly selective α-adrenergic receptor inhibitor, with an affinity for α1 receptors that is 5,400 to 24,000 times stronger than its affinity for α2 receptors. It is 13 times more effective in inhibiting increased urethral pressure than it is in inhibiting vascular dilatation pressure. It is suitable for moderate to severe lower urinary tract obstruction. The short-term goal is to relieve the patient's lower urinary tract symptoms, while the long-term goal is to delay the clinical progression of the disease.
Ningbituo® Tofacitinib Citrate Tablets
Tofacitinib is an oral selective Janus kinase (JAK) inhibitor, a targeted immunosuppressant. JAK is an intracellular enzyme that transmits signals generated by the interaction of cytokines and receptors on the cell membrane. Within the signaling pathway, JAK phosphorylates and activates signal transcription factors and transcriptional activators (STAT), thereby regulating gene expression and cytokine production.
Shikang® Apixaban Tablets
Shikang® Apixaban Tablets are an oral, potent, and highly selective direct Factor Xa inhibitor.
